The Joint Committee on Vaccination and Immunisation (JCVI) has previously advised:
- 2 doses of the Pfizer-BioNTech COVID-19 vaccine in children and young people aged 16 to 17 years with an underlying health condition that places them at higher risk from serious COVID-19 (‘at-risk group’)
- a first dose of Pfizer-BioNTech COVID-19 vaccine for those not in an at-risk group
On 19 October 2021 JCVI considered options for offering a second dose to persons aged 16 to 17 years who are not in an at-risk group.
JCVI advises that young people aged 16 to 17 years who are not in an at-risk group should be offered a second dose of Pfizer-BioNTech (Comirnaty) COVID-19 vaccine.
The second vaccine dose should be given 12 weeks or more following the first vaccine dose.
For persons who have had proven SARS-CoV-2 infection and a first dose of vaccine, the second vaccine dose should be given 12 weeks or more following the first vaccine dose, or 12 weeks following SARS-CoV-2 infection, whichever is later.